Molecular-targeted therapies for the treatment of cysticfibrosis(CF) rely on small-molecule modulators that rescue the activity ofthe defective CF transmembrane conductance regulator (CFTR) anionchannel. The gene discussed is CFTR; the disease is cystic fibrosis.